🟢 Telix Pharmaceuticals is trading 4.08% up today after BiPASS enrollment and FDA NDA pathway alignment

Telix Pharmaceuticals is trading 4.08% up at A$16.33 after completing patient enrollment in the Phase 3 BiPASS study and aligning with the FDA on a potential NDA pathway for Illuccix and Gozellix.

• The development could support reimbursement and broader patient access if approved.
• This is the strongest company-specific explanation identified, although Telix did not explicitly attribute the share move to it.